Amyloidosis: causes, types, diagnosis, and clinical significance

Characteristics and pathology

At the microscopic level amyloid fibrils have a characteristic beta‑sheet conformation and bind certain stains that allow pathologists to identify them in biopsy specimens. When examined under polarized light after Congo red staining, amyloid classically shows an "apple‑green" birefringence. The deposits are extracellular and may replace normal tissue, impairing organ function. Organs commonly affected in systemic disease include the kidneys, heart, liver, peripheral nerves and gastrointestinal tract; localized deposits may occur in skin, the respiratory tract, or other single sites.

Classification and common types

Amyloidosis is classified according to the biochemical identity of the fibril protein. More than two dozen human proteins are known to form amyloid, and the most frequently encountered types include:

• AL (light‑chain) amyloidosis — fibrils derived from immunoglobulin light chains produced by clonal plasma cells; often systemic and may involve heart and kidneys.
• AA (secondary) amyloidosis — fibrils composed of fragments of serum amyloid A protein, typically associated with chronic inflammatory conditions.
• ATTR amyloidosis — fibrils derived from transthyretin, which can be the normal (wild‑type) protein or a variant from a genetic mutation; often affects the heart and nerves.
• Localized amyloidoses — produced by local precursor proteins at the site of deposition, such as amyloid in the brain associated with Alzheimer-type pathology or in localized nodules.

Because the underlying proteins and mechanisms differ, accurate typing of amyloid is essential for prognosis and therapy.

Clinical presentation and diagnosis

Symptoms depend on which organs are affected and the extent of deposition. Renal involvement typically presents with proteinuria and progressive kidney dysfunction; cardiac involvement can cause restrictive cardiomyopathy and arrhythmias; neuropathy often produces numbness, tingling and autonomic symptoms. Because early manifestations are nonspecific, diagnosis often requires a combination of clinical suspicion, imaging, laboratory studies, and tissue biopsy. Fat pad aspiration or affected‑organ biopsy with Congo red staining and additional biochemical or immunohistochemical methods is used to confirm and type the amyloid protein.

Treatment and prognosis

Treatment strategies aim to reduce production of the offending precursor protein and support affected organs. For AL amyloidosis, therapies that suppress the abnormal plasma cell clone (for example, chemotherapy regimens used in plasma cell disorders) can reduce new light‑chain production. For ATTR amyloidosis, options include medicines that stabilize transthyretin, agents that reduce its production, or, in selected patients, liver transplantation or cardiac interventions. Management also addresses organ‑specific complications such as heart failure or renal impairment. Prognosis varies greatly by type, organ involvement and response to therapy; early diagnosis and targeted treatment improve outcomes.

History, epidemiology and notable facts

The word "amyloid" was introduced in the mid‑19th century to describe starch‑like deposits seen in tissues. Modern understanding identifies amyloid as proteinaceous fibrils with distinctive structural properties. Amyloidosis is rare compared with many chronic diseases, and its true prevalence depends on the subtype and population studied. Awareness of the diversity of amyloid‑forming proteins has increased with advances in biochemical and genetic testing.

Several public figures have been associated with amyloidosis in media reports; examples include Martin McGuinness, David Lange, Robert Jordan and Robert P. Casey. Their cases have helped raise public awareness of the disease.

Because amyloidosis spans multiple medical specialties and has many subtypes, effective care often requires coordination between hematologists, cardiologists, nephrologists, neurologists and pathologists. Ongoing research into the molecular mechanisms of protein misfolding is driving development of new diagnostics and therapies aimed at halting fibril formation or clearing deposits.